Astra Zeneca: A Drug Megamerger That's Working

It's off to a strong start, but the drug pipeline needs tending

For AstraZeneca CEO Tom McKillop, it was sweet vindication. On Oct. 28, Anglo-Swedish drug company AstraZeneca PLC shocked the industry by coming out with growth numbers that far exceeded expectations. Third-quarter drug sales in the U.S., the world's fastest-growing market, soared 60%, to $1.9 billion, and worldwide sales were up 31%, to $3.7 billion, compared with the same period last year. AstraZeneca increased pretax profits 54%, to $941 million.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.